mRNA Cancer Vaccine

Phase 3 clinical trial results at the ESMO Congress reveal that the personalized mRNA-4157 vaccine prevents recurrence and metastasis in high-risk melanoma. Swipe to see →

THE ENIGMA OF TUMOR RECURRENCE

Cutaneous melanoma remains the most aggressive and lethal form of skin malignancy due to its exceptional propensity for early systemic dissemination.

THE ARCHITECTURE OF INDIVIDUALIZED NEOANTIGENS

The manufacturing pipeline for intismeran autogene initiates immediately following surgical resection of the primary tumor or metastatic regional lymph nodes.

CLINICAL EVIDENCE FROM THE PHASE 3

The pivotal, global, randomized Phase 3 INTerpath-001 clinical study, registered with the National Institutes of Health, enrolled 1,089 patients with completely resected high-risk stage IIB, IIC, III, and IV cutaneous melanoma.

A PARADIGM SHIFT IN ONCOLOGY

For decades, standard oncological practice following curative-intent surgical resection adhered to a fundamentally reactive watch-and-wait philosophy.

CLINICAL EXPANSION

The statistical success of the INTerpath-001 trial has catalyzed rapid expansion of the individualized mRNA vaccine platform across a spectrum of highly lethal solid tumors.

📰 FULL ARTICLE

Visit our portal and read the full story!